November 9, 2022
Beckley Psytech announces first participant dosed in Phase I trial of ELE-101, a novel intravenous formulation of psilocin
Beckley Psytech has dosed the first participant in their Phase I single-ascending dose (SAD) study of ELE-101, with top-line results expected in H1 2023. ELE-101 is a patent-protected, next-generation formulation of psilocin, the active metabolite of psilocybin, currently under clinical development for depression. ELE-101 is the second clinical-stage psychedelic compound in Beckley Psytech’s portfolio alongside BPL-003, the company’s lead candidate for upcoming MHRA-approved Phase IIa studies in depression and Alcohol Use Disorder (AUD).